Table 3 Outcome of the study population after 1 year of follow up
Outcome | Total n (%) N = 156 | Male n (%) N = 80 | Female n (%) N = 76 | P |
|---|---|---|---|---|
At referral | ||||
 Dialysis | 37 (23.7) | 16 (20.0) | 21 (27.6) | 0.263 |
 Vascular access | ||||
  CVCa | 34 (91.9) | 16 (100.0) | 18 (85.7) |  |
  AVFb | 3 (8.1) | 0 (0.0) | 3 (14.3) | 0.243 |
 Dialysis indication, n = 37 | ||||
  Uremic syndrome | 30 (81.1) | 12 (75.0) | 18 (85.7) | 0.437 |
  Acute pulmonary edema | 6 (16.2) | 3 (18.8) | 3 (14.3) | > 0.999 |
  Severe hyperkalemia | 4 (10.8) | 212.5) | 2 (9.5) | > 0.999 |
  Uremic encephalopathy | 3 (8.1) | 1 (6.3) | 2 (9.5) | > 0.999 |
At 1 year | ||||
 Unknown | ||||
  Transfer to another hospital | 5 (3.2) | 3 (3.8) | 2 (2.6) | 0.692 |
  Lost to follow up | 64 (41.0) | 34 (42.5) | 30 (39.5) | 0.701 |
 Known, n = 87 | ||||
  Deceased | 43 (49.4) | 21 (48.8) | 22 (50.0) | 0.914 |
  On chronic dialysis | 25 (28.7) | 12 (27.9) | 13 (29.5) | 0.866 |
  Alive and not on dialysis | 19 (21.8) | 10 (23.3) | 9 (20.5) | 0.752 |
 CD4c, n = 21 | 380 (265–598.5) | 353.5 (251.5–588.8) | 476 (271.5–685) | 0.804 |